Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune
No biopharma company has suffered as many clinical setbacks in Alzheimer’s drug research as Eli Lilly. But that hasn’t stopped the pharma giant from driving back toward the clinic with a deal worth close to $2 billion for a portfolio of preclinical tau aggregation inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
